Dividends & Buybacks ·
On September 14, 2026, the Board of Directors authorized a new share repurchase program allowing the company to buy…
ASNDAscendis Pharma A/S
On September 14, 2026, the Board of Directors authorized a new share repurchase program allowing the company to buy back up to $400 million of ordinary shares. Purchases may be executed through open market transactions, privately negotiated deals, block trades, accelerated share repurchases, or 10b5-1 plans at management's discretion based on market conditions and share price. The program does not mandate a specific number of shares and can be modified, suspended, or terminated without notice. Ascendis Pharma A/S is a biotechnology company focused on developing therapies for rare diseases.